138 related articles for article (PubMed ID: 3235884)
1. [Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma].
Ihara Y; Shimizu T; Kawaguchi K; Yomura W; Fujiwara T; Inoue K
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Nov; 40(11):1711-8. PubMed ID: 3235884
[TBL] [Abstract][Full Text] [Related]
2. [Histochemical analysis of uterine cervical adenocarcinoma with reference to mucosubstances and distribution of CEA, CA125 and CA19-9].
Maruyama C; Yamamichi N; Konishi F
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Apr; 40(4):429-36. PubMed ID: 3163714
[TBL] [Abstract][Full Text] [Related]
3. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma.
Takeshima N; Shimizu Y; Umezawa S; Hirai Y; Chen JT; Fujimoto I; Yamauchi K; Hasumi K
Gynecol Oncol; 1994 Sep; 54(3):321-6. PubMed ID: 8088608
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
5. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
6. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
[TBL] [Abstract][Full Text] [Related]
8. [Analysis of the levels of CA125, CEA and CA19-9 in the cervical mucus samples obtained at various phases of the menstrual cycle and with inflammatory diseases of the uterine cervix].
Nanbu Y; Fujii S; Konishi I; Nonogaki H; Kobayashi F; Sagawa N; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1988 Oct; 40(10):1519-24. PubMed ID: 3225482
[TBL] [Abstract][Full Text] [Related]
9. [Clinical significance of CA19-9 for endometriosis].
Watanabe J; Johboh T; Hata H; Kuramoto H
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Feb; 42(2):155-61. PubMed ID: 2313144
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistochemical analysis of CA19-9, SLX, and CA125 in adenoid cystic carcinoma of trachea and bronchus].
Tamura S; Yamaguchi K; Terada M; Nakano T; Maeda J; Iwahashi N; Hada T; Higashino K
Nihon Kyobu Shikkan Gakkai Zasshi; 1992 Mar; 30(3):407-11. PubMed ID: 1314919
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical investigation of vimentin of uterine endometrial and endocervical adenocarcinoma].
Ohwada M; Suzuki M; Tamada T
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Sep; 42(9):1237-43. PubMed ID: 2212824
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
[TBL] [Abstract][Full Text] [Related]
13. CA19-9, CA125 and CEA in endometrial carcinoma tissue and its relation to hormone receptor content and histological grading.
Neunteufel W; Bieglmayer C; Breitenecker G
Arch Gynecol Obstet; 1988; 244(1):47-52. PubMed ID: 2853610
[TBL] [Abstract][Full Text] [Related]
14. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
15. [Significance of tumor markers in the treatment of patients with ovarian malignancies].
Tomoda Y; Kano T; Furuhashi Y; Mizuno K; Kamiya N; Mizuno K; Sakakibara K; Ohta M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3027-33. PubMed ID: 2445293
[TBL] [Abstract][Full Text] [Related]
16. A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma.
Gadducci A; Ferdeghini M; Prontera C; Giordano P; Cristofani R; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(4):283-8. PubMed ID: 2245812
[TBL] [Abstract][Full Text] [Related]
17. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
20. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
